KR100771438B1 - A cosmetic composition for acne improvement having sebum secretion and anti-inflammation effects - Google Patents
A cosmetic composition for acne improvement having sebum secretion and anti-inflammation effects Download PDFInfo
- Publication number
- KR100771438B1 KR100771438B1 KR1020060059044A KR20060059044A KR100771438B1 KR 100771438 B1 KR100771438 B1 KR 100771438B1 KR 1020060059044 A KR1020060059044 A KR 1020060059044A KR 20060059044 A KR20060059044 A KR 20060059044A KR 100771438 B1 KR100771438 B1 KR 100771438B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- acne
- cosmetic composition
- pantothenic acid
- sebum secretion
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 42
- 206010000496 acne Diseases 0.000 title claims abstract description 42
- 239000002537 cosmetic Substances 0.000 title claims abstract description 21
- 230000006872 improvement Effects 0.000 title claims description 7
- 210000002374 sebum Anatomy 0.000 title abstract description 33
- 230000028327 secretion Effects 0.000 title abstract description 28
- 230000000694 effects Effects 0.000 title description 15
- 206010061218 Inflammation Diseases 0.000 title description 9
- 239000000284 extract Substances 0.000 claims abstract description 59
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims abstract description 58
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 33
- 239000011713 pantothenic acid Substances 0.000 claims abstract description 29
- 235000019161 pantothenic acid Nutrition 0.000 claims abstract description 29
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229940055726 pantothenic acid Drugs 0.000 claims abstract description 28
- 240000004922 Vigna radiata Species 0.000 claims abstract description 22
- 235000010721 Vigna radiata var radiata Nutrition 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 12
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229940058015 1,3-butylene glycol Drugs 0.000 claims abstract description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 claims abstract description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract 4
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 claims description 18
- 235000018185 Betula X alpestris Nutrition 0.000 claims description 16
- 235000018212 Betula X uliginosa Nutrition 0.000 claims description 16
- -1 pack Substances 0.000 claims description 16
- 229940069765 bean extract Drugs 0.000 claims description 13
- 238000009472 formulation Methods 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 10
- 239000006071 cream Substances 0.000 claims description 8
- 239000006210 lotion Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000006260 foam Substances 0.000 claims 1
- 239000012046 mixed solvent Substances 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 21
- 230000005764 inhibitory process Effects 0.000 abstract description 7
- 239000002904 solvent Substances 0.000 abstract description 6
- 235000021501 Rumex crispus Nutrition 0.000 abstract description 4
- 244000207667 Rumex vesicarius Species 0.000 abstract description 4
- 241001606229 Betula platyphylla var. japonica Species 0.000 abstract description 3
- 235000002359 Betula platyphylla var japonica Nutrition 0.000 abstract 2
- 230000000052 comparative effect Effects 0.000 description 20
- 210000003491 skin Anatomy 0.000 description 17
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 235000019441 ethanol Nutrition 0.000 description 12
- 239000008213 purified water Substances 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 230000002421 anti-septic effect Effects 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 210000003780 hair follicle Anatomy 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 229920001214 Polysorbate 60 Polymers 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000004209 hair Anatomy 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 4
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 4
- 229940113124 polysorbate 60 Drugs 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 210000001732 sebaceous gland Anatomy 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 229920002554 vinyl polymer Polymers 0.000 description 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229940055019 propionibacterium acne Drugs 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 206010037888 Rash pustular Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 229960002903 benzyl benzoate Drugs 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- 239000010977 jade Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- YNBADRVTZLEFNH-UHFFFAOYSA-N methyl nicotinate Chemical compound COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 2
- 208000010805 mumps infectious disease Diseases 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 208000029561 pustule Diseases 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- OWGDCENIOHFPHD-UHFFFAOYSA-N 16,16,16-trihydroxyhexadecanoic acid Chemical compound OC(=O)CCCCCCCCCCCCCCC(O)(O)O OWGDCENIOHFPHD-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 241000380130 Ehrharta erecta Species 0.000 description 1
- 244000148064 Enicostema verticillatum Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 241000208467 Macadamia Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010027626 Milia Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000809 air pollutant Substances 0.000 description 1
- 231100001243 air pollutant Toxicity 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 229940079894 benzophenone-9 Drugs 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- QDCHWIWENYCPIL-UHFFFAOYSA-L disodium;4-hydroxy-5-(2-hydroxy-4-methoxy-5-sulfonatobenzoyl)-2-methoxybenzenesulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC(S([O-])(=O)=O)=C(OC)C=C1O QDCHWIWENYCPIL-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000006355 external stress Effects 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960001238 methylnicotinate Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Birds (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 피지분비 억제 및 항염증 효과를 가지는 여드름 개선용 화장료 조성물에 관한 것으로서, 보다 상세하게는 피지 분비 억제 기능을 갖는 판토텐산과 항염증 효과를 갖는 녹두 추출물, 자작나무 추출물, 소루쟁이 추출물로 구성되는 군으로부터 선택된 적어도 1종 이상의 추출물의 상승 작용에 의하여 피부 여드름 예방 및 치료 효과를 극대화할 수 있는 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition for improving acne having a sebum secretion inhibitory and anti-inflammatory effect, and more particularly, composed of pantothenic acid having a sebum secretion inhibitory function and a mung bean extract having an anti-inflammatory effect, a birch extract, and an extract It relates to a cosmetic composition that can maximize the skin acne prevention and treatment effect by the synergistic action of at least one extract selected from the group consisting of.
여드름(심상성 좌창 : Acne vulgaris)이란 모공이 좁아지거나 막혀 피지가 배출되지 못해 생기는 피부병이다. 털을 만드는 모낭에는 털에 기름을 분비하여 촉촉하게 하는 피지선이 있는데. 이 피지선의 분비가 늘어나거나 모낭 입구가 막히면 여드름균의 증식이 활발하여 여드름을 일으킨다. 여드름의 원인은 여러 가지가 있지만 남성 호르몬인 안드로겐(androgen), 여드름을 일으키는 세균 즉, 프로피오니박테리움 아크네(Propionibacterium acnes)의 증식 및 피지 분비 증가가 가장 중요하다. 여드름 환자의 경우 안드로겐이 피지선을 자극하여 피지 분비를 증가시키고, 이렇게 증가된 피지들이 죽은 피부세포들과 엉키고 뭉쳐지게 되면서 모낭 입구를 막는다. 이렇게 막힌 모낭 입구는 혐기성 세균인 프로피오니박테리움 아크네가 자랄 수 있는 환경을 제공하게 되고, 이들이 분비한 리파아제(lipase)들이 피지를 분해하여, 그 분해산물이 모낭에 자극을 주어 결국 염증을 일으킨다. 이렇게 생기는 여드름은 피부 중 가장 잘 보이는 부위, 특히 얼굴, 가슴, 등,목 등에 잘 나타난다. Acne (acne vulgaris) is a skin disease caused by narrowing or clogging pores and the release of sebum. The hair follicles that make up the hair have sebaceous glands that secrete oil into the hair. Increased secretion of these sebaceous glands or clogged hair follicles, acne bacteria proliferate, causing acne. There are many causes of acne, but the most important is the proliferation and sebum secretion of the androgen (androgen), the acne-causing bacterium, or propionibacterium acnes. In acne patients, androgens stimulate sebaceous glands to increase sebum secretion, and the increased sebum becomes entangled and clumped with dead skin cells, blocking the entrance of the hair follicles. The clogged follicle openings provide an environment for the growth of anaerobic bacteria, propionibacterium acne, and the secreted lipases break down sebum, causing the hair follicles to irritate and eventually become inflamed. This acne is most visible on the skin, especially on the face, chest, back and neck.
여드름은 증상에 따라 비염증성 여드름과 염증성 여드름으로 나눌 수 있다. 비염증성의 경우 여드름의 가장 초기에 나타나는 여드름의 전형적인 병변으로 막혀있던 피지 덩어리에 의해 피부가 늘어나면서 생기며, 계속 진행되면서 개방형 면포(blackhead)와 폐쇄성 면포(whitehead)로 발전할 때 나타난다. 개방형은 모낭 내의 축적물이 피부 표면에 노출되어 보이면서 검은색을 띠고 있는 것을 말하며 폐쇄형은 피지 덩어리가 피부 표면에 노출되지 않아 피부색이나 흰색의 혹 같아 보이는 것을 말한다. 염증성 여드름의 기본적인 병변에는 구진(papule), 농포(pustule), 결절(tuber)의 세가지 형태가 있다. 구진은 염증에 의해 생성되는 좁쌀 크기의 발진을 말하며, 농포는 약간 돋아올라 보이는 발진으로, 내부에 있는 고름 때문에 황색 또는 회백색으로 보인다. 결절은 면포 내의 내용물이 밖으로 빠져 나와 주변의 피부 조직에 면역 반응을 유도함으로써 농을 형성하게 된다.Acne can be divided into non-inflammatory and inflammatory acne depending on the symptoms. Non-inflammatory is caused by the skin being stretched by a sebum mass that has been blocked by the typical lesions of acne, which develops into open and closed whiteheads. The open type means that the accumulation in hair follicles is exposed to the surface of the skin and is black. The closed type means that the sebum mass is not exposed to the skin surface and looks like skin color or white bumps. There are three basic types of inflammatory acne: papules, pustules, and tubers. Papules are millet-sized rashes produced by inflammation, and pustules are slightly raised rashes that appear yellow or grayish white due to pus inside. The nodule forms the pus by the contents of the scrim come out and induce an immune response to the surrounding skin tissue.
여드름의 예방과 치료는 과도한 피지 분비 억제와 염증완화를 통해서 얻을 수 있다. 따라서, 그 원인을 복합적으로 제거를 한다면 여드름을 매우 효과적으로 억제할 수 있게 된다. 특히, 여드름은 근래에 와서 외부적 스트레스, 대기 오염물, 호르몬 불균형 등으로 청소년 뿐만 아니라 성인에게서 유발되는 경향이 증가되고 있고, 이 현상은 해마다 현저해지고 있기 때문에 여드름과 관련된 방법들이 많이 제시되고 있다. 여드름과 관련된 피부 트러블을 개선하는 방법으로 살리실릭산 및 트리클로산(triclosan) 및 트리하이드록시팔미틱산을 화장료 조성물에 적용함으로써 모공을 열어주고 피지 분비를 촉진하여 여드름의 예방 및 치료하는 방법이 개시되고 있고(대한민국 공개특허 제2004-0089072호), 올리고사카라이드를 복용함으로써 피지선에서의 피지 분비량을 감소시켜 피지분비를 억제하는 방법을 개시하고 있다(일본 특허공개 평 05-294836호). 또한, 프로피오니박테리움 아크네에 항균력을 가진 제비꽃 추출물을 화장료에 적용시켜 여드름의 예방하는 방법이 제시되고 있다(대한민국 공개특허 제2002-0082616호). Acne prevention and treatment can be achieved through excessive sebum secretion and inflammation relief. Therefore, if you remove the cause in combination, acne can be suppressed very effectively. In particular, acne has recently been increased in adolescents as well as adults due to external stress, air pollutants, hormonal imbalances, etc. This phenomenon is becoming more noticeable each year, so many methods related to acne have been proposed. As a method for improving skin problems associated with acne, salicylic acid and triclosan and trihydroxy palmitic acid are applied to cosmetic compositions to open pores and promote sebum secretion to prevent and treat acne. (Korean Patent Laid-Open Publication No. 2004-0089072) discloses a method of suppressing sebum secretion by reducing the amount of sebum secretion in sebaceous glands by taking oligosaccharides (Japanese Patent Laid-Open No. 05-294836). In addition, a method of preventing acne by applying a violet extract having antimicrobial activity to propionibacterium acne to cosmetics has been proposed (Korean Patent Publication No. 2002-0082616).
본 발명의 주된 목적은 피지 분비 억제 기능을 갖는 판토텐산과 항염증 효과를 갖는 녹두 추출물, 자작나무 추출물, 소루쟁이 추출물로 구성되는 군으로부터 선택된 적어도 1종 이상의 추출물의 상승 작용에 의하여 피부 여드름 예방 및 치료 효과를 극대화할 수 있는 화장료 조성물을 제공하는 것이다.The main object of the present invention is to prevent and treat skin acne by synergistic action of at least one extract selected from the group consisting of pantothenic acid having a sebum secretion inhibitory function, and mung bean extract, birch extract, and thorax extract having an anti-inflammatory effect. It is to provide a cosmetic composition that can maximize the effect.
본 발명은 여드름 피부용 화장료 조성물에 관한 것으로서, 유효성분으로 판토텐산을 총 중량에 대하여 0.01 ~ 10.0중량%의 양으로 함유하고, 서로 다른 자극완화 메커니즘을 갖는 유효성분으로서 녹두추출물, 자작나무추출물 및 소루쟁이추출물로 구성되는 군으로부터 선택된 적어도 1종 이상의 추출물을 조성물 총 중량에 대하여 0.001∼20중량%, 바람직하게는 0.5∼10중량%의 양으로 함유한다. 이는 20중량%이상의 고농도에서는 피부자극을 유발할 수 있으며, 0.001중량%이하의 저농도에서는 효과가 미비하기 때문이다.The present invention relates to a cosmetic composition for acne skin, the active ingredient contains pantothenic acid in an amount of 0.01 to 10.0% by weight based on the total weight, mung bean extract, birch extract and sprout At least one extract selected from the group consisting of extracts is contained in an amount of 0.001 to 20% by weight, preferably 0.5 to 10% by weight, based on the total weight of the composition. This may cause skin irritation at high concentrations of more than 20% by weight, and the effect is insufficient at low concentrations of less than 0.001% by weight.
삭제delete
본 발명에서 유효성분으로 이용되는 판토텐산 또는 판토테네이트는 비타민 B 복합체의 구성원이며 비타민 B5로 알려져 있고, 가축 및 인간을 포함한 포유류에게 필요한 영양소이다. 판토텐산의 기능으로는 피부의 보습유지기능을 향상시키고 피부의 재생을 자극하는 것으로 알려져 있으며, 건성 피부는 부드럽고 탄력적으로 변하게 한다. 판토텐산은 염증방지 및 가려움증 방지에 효과가 있을 뿐 아니라 머리결을 강하고 부드럽게 할 뿐만 아니라 손상된 머리카락을 복원하고 윤기있게 만들기 때문에 모발성장용에 쓰이기도 한다.Pantothenic acid or pantothenate used as an active ingredient in the present invention is a member of the vitamin B complex and known as vitamin B 5 , and is a nutrient necessary for mammals including livestock and humans. Pantothenic acid is known to improve skin moisturizing function and stimulate skin regeneration. Dry skin is soft and elastic. Pantothenic acid is not only effective for preventing inflammation and itching, but it is also used for hair growth because it not only strengthens and softens the hair, but also restores and lusters damaged hair.
본 발명의 또 다른 유효성분으로 이용되는 녹두(綠豆)는 쌍떡잎식물 장미목 콩과에 속하는 한해살이풀로서 원산지는 인도로 추정하며 한국, 중국, 인도 등의 아시아지역에 주로 분포한다. 녹두는 따뜻한 기후의 양토(壤土: 모래와 점토가 알맞게 섞인 검은빛의 흙)에서 잘 자라며 높이는 30-80cm 정도이다. 줄기는 가늘고 세로로 난 맥이 있고 10여 개의 마디가 있으며 가지를 친다. 잎은 한쌍의 떡잎과 갓 생겨난 잎이 나온 뒤, 3개의 작은잎으로 된 겹잎이 나온다. 꽃은 노란색으로 8월에 피며 잎겨드랑이에 몇 개씩 모여나나 3-4쌍만이 열매를 맺는다. 열매는 협과로 처음에는 녹색이지만 익으면 검어지고 길고 거친 털로 덮인다. 길이 5-6cm이고 한 꼬투리에 10-15개의 종자가 들어 있다. 종자는 녹색인 것이 많으나 노란색, 녹색을 띤 갈색, 검은빛을 띤 갈색인 것도 있다. 품종을 나누지 않고 종자의 빛깔에 따라 노란색, 녹색을 띤 갈색, 검은빛을 띤 갈색 녹두로 구분하나 녹색 녹두가 전체의 90%를 차지한다. 성분은 녹말 53-54%, 단백질 25-26%로 영양가가 높고 향미가 좋다.Mung bean (綠 豆) used as another active ingredient of the present invention is a perennial herb belonging to the dicotyledon rose rosaceae, its origin is assumed to be India, and is mainly distributed in Asia such as Korea, China, and India. Mung beans grow well on warm climate loam (a black soil mixed with sand and clay) and are about 30-80 cm in height. The stem has a thin, vertical vein, about 10 nodes, and branches. The leaves come out with a pair of cotyledons and freshly formed leaves, followed by three leaflets. Flowers are yellow and bloom in August, gathering several on axilla, but only 3-4 pairs bear fruit. Fruits are edible, initially green, but ripened and covered with long, coarse fur. It is 5-6cm long and contains 10-15 seeds in one pod. Seeds are often green, but yellow, greenish brown, and blackish brown. The varieties are divided into yellow, greenish brown, and blackish brown mung beans, depending on the color of the seeds, but green mung beans make up 90% of the total. The ingredients are 53-54% starch and 25-26% protein.
녹두(Phaseolus aureus, Phaseolus radiatus, Mung Bean, Green Bean)는 원래 강한 해열, 해독 작용을 가지고 있어 한방에서 해열, 해독제로 널리 사용되는 것으로서, 동의보감 등의 문헌에 나타난 피부미용과 관련된 처방을 보면 비누처럼 사용하여 얼굴이 옥처럼 예뻐진다는 옥용서시산, 피부불순물을 제거하고 건조한 피부에 효과적인 여옥산, 기미를 없애주는 영기여옥산, 여름에 잘 발생하는 땀띠를 제거해 주는 옥녀영 등에 사용되고 있다. 그리고, 피부 각질층에 피부 사상균이 침투하여 발생하는 황수창 (부스럼), 옹종 (종기) 및 볼거리 (유행성 이하선염) 등에서도 녹두가 효과적으로 사용되어 왔다. 본 발명자들이 확인한 바에 의하면 녹두추출물은 항산화 작용, 자유라디칼 소거 작용, 피부 세포 활성 및 재생력 강화를 통한 피부 세포의 자극원에 대한 저항력 증가 작용이 매우 뛰어나며, 히스타민 유리 억제 작용 등을 보여 우수한 자극완화 효과를 나타낸다. Mung beans (Phaseolus aureus, Phaseolus radiatus, Mung Bean, Green Bean) have strong antipyretic and detoxifying effects, and are widely used as antipyretic and antidote in oriental medicine. It is used for jade yongsushi acid, which makes your face look like jade, yeooksan, which is effective for removing skin impurities and dry skin, and yeogiyeooksan, which removes blemishes, and Oknaeyoung, which removes sweat bands that occur in summer. In addition, mung beans have been used effectively in yellow spear (bushrum), carbuncle (boil) and mumps (pandemic mumps) caused by dermal filamentous fungi in the stratum corneum. According to the inventors, the mung bean extract has an excellent effect of increasing the resistance to the stimulating agent of skin cells through antioxidant activity, free radical scavenging action, skin cell activity and regeneration, and shows histamine release effect. Indicates.
본 발명의 또 다른 유효성분으로 이용되는 자작나무 (Betula Platyphylla Japonica)는 북부지방의 산악지역에 자라는 자작나무과에 속하는 교목으로서 키는 20m에 달한다. 수피(樹皮)는 흰색이며 수평으로 벗겨지고 어린가지는 점이 있는 붉은 갈색이다. 잎은 길이가 5-7cm인 3각형의 난형으로 끝은 뾰족하고 가장자리에는 톱니가 있으며, 잎자루는 길이가 2cm정도이다. 꽃은 4, 5월경에 암꽃이 피며 같은 시기, 같은 그루에 수꽃이 긴 미상 (尾狀) 꽃차례를 이루며 잎보다 먼저 핀다. 열매는 9월에 익는데, 좌우로 넓은 날개가 달려 있다. 열매가 달리는 원통형의 자루는 길이가 4cm로 밑으로 처진다. 나무의 즙(汁)은 자양강장과 피부병에 쓰이지만 도시 공해에는 매우 약하다. 자작나무 껍질은 약재로도 퍽 중요하게 쓰여 왔는데 간경에 작용하고 열을 내리고 습을 없애며 기침을 멈추고 담을 삭이는 작용이 있다. 또한, 해독작용도 탁월하여 염증을 없애는 효과가 상당히 강하며 이뇨작용이 있어서 신장염이나 부종을 고치는 데에도 쓸 수 있어 한의학과 민간에서는 백화피, 화피 등으로 부르며 황달, 설사, 신장염, 폐결핵, 위염, 갖가지 옹종 등의 치료에 이용해 왔다. 그리고, 아라키돈산, 프로스타글란딘, 류코트리엔 등과 같은 염증 매개 물질의 생성 억제 효과 등을 보여 우수한 자극 완화 효과를 나타낸다.The birch tree (Betula Platyphylla Japonica), which is used as another active ingredient of the present invention, is a tree belonging to the birch family, which grows in the mountainous region of the northern part, reaching 20m in height. Bark is white, peeled horizontally, and young branches are reddish brown with spots. Leaves are triangular ovate, 5-7cm long, pointed at the end, sawtooth at the edge, petioles about 2cm long. Flowers bloom in April and May, and female flowers bloom at the same time and in the same tree with long doe inflorescences, which bloom before leaves. The fruit ripens in September, with wide wings from side to side. Cylindrical sack with fruit hangs down 4cm long. The juice of the tree is used for nourishing tonic and skin diseases, but very weak for urban pollution. Birch bark has been used as an important medicine as a medicine, it acts on the liver, lowers heat, removes moisture, stops coughing and cuts off the walls. In addition, the detoxification effect is very strong to remove inflammation, and diuretic effect can be used to relieve nephritis or edema. It has been used for the treatment of carbuncles and the like. In addition, it exhibits an inhibitory effect on the production of inflammatory mediators such as arachidonic acid, prostaglandin, leukotriene, and the like, and shows an excellent stimulating effect.
본 발명의 또 다른 유효성분인 소루쟁이 (Rumex crispus)는 양제근, 솔쟁이, 송구지 등으로 불리며, 한여름이면 줄기가 다 말라 버렸다가 선선하면 다시 자라나는 여뀌과의 다년생 풀이다. 어린 잎은 나물로 먹기도 하며, 백선, 무좀, 습진 등에 효과가 있다고 한다. 예로부터 민간에서는 개선, 옴, 피부암 등의 피부병에 사용하였으며, 방광염, 대장염 등에도 달여서 사용했다고 한다. 가을에 뿌리를 깨서 둥글게 말아 햇볕에 말린 것을 양제근이라고 한다. 소루쟁이추출물은 엘라스타제, 히알루로니다제의 분비 및 작용 억제 효과가 매우 우수하며, IL-8 (Interleukin-8) 등과 같은 염증 매개 사이토카인의 분비 억제를 통해 우수한 항염증 효과를 나타내는 것으로 알려져 있다.
특히, 본 발명에서는 항염증 효과 성분으로 녹두 추출물, 소루쟁이 추출물 및 자작나무 추출물로 이루어진 군에서 선택된 1종 이상을 함유하며, 이러한 유효 성분은 자극 완화 효과를 가져 염증 매개 물질을 억제할 수 있는 효과 등을 보여 피부의 여드름을 개선하여 여드름과 관련된 피부 트러블을 개선할 수 있는 여드름 개선용 화장료 조성물을 제공하는데 유용하다.Rumex crispus (Rumex crispus) is another active ingredient of the present invention is called yangjegeun, solbang, muzzle, etc., is a perennial grass of the perennial herb that dries up in the summer and grows again when cool. Young leaves are eaten as herbs, and are said to be effective for ringworm, athlete's foot, and eczema. Since ancient times, it has been used in skin diseases such as amelioration, scabies and skin cancer. It is called Yangje-geun when the roots are cracked and rolled up in the autumn and dried in the sun. Soruja extract is very effective in suppressing the secretion and action of elastase and hyaluronidase, and is known to exhibit excellent anti-inflammatory effect through the inhibition of inflammation mediated cytokines such as IL-8 (Interleukin-8). have.
In particular, the present invention contains at least one member selected from the group consisting of mung bean extract, thorax extract and birch extract as an anti-inflammatory effect component, such an active ingredient has a stimulating alleviating effect to suppress the inflammatory mediators It is useful to provide a cosmetic composition for improving acne by improving the acne of the skin by showing the back and so on.
본 발명의 피부개선 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제 함유 클렌징 등으로 제형화될 수 있으나, 이에 한정된 것은 아니다. The skin improvement cosmetic composition of the present invention may be prepared in any formulation commonly prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing And the like, but are not limited thereto.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 클리콜, 실리콘, 벤토나이트, 실리카, 탈크, 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, the carrier components include animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide and the like. Can be used.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글라이콜, 1,3-부틸 글라이콜, 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글라이콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or emulsion, a solvent, solubilizer or emulsifier is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol , Fatty acid esters of 1,3-butyl glycol, oils, glycerol aliphatic esters, polyethylene glycols or sorbitan.
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진제를 포함할 수 있다. When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, in particular in the case of a spray, additionally chlorofluorohydrocarbon, propane Propellant such as butane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다. When the formulation of the present invention is a solution or emulsion, a solvent, solubilizing agent or emulsifying agent is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올, 또는 프로필렌 글라이콜과 같은 액상의 희석제, 에톡시화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트등이 이용될 수 있다.When the dosage form of the present invention is a suspension, a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester as a carrier component , Microcrystalline cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.
본 발명의 제형이 계면활성제 함유 클링징인 경우에는 담체 성분으로서 지방 족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is a surfactant-containing klings, as a carrier component, an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, isethionate, an imidazolinium derivative, a methyltaurate, a sarcosinate, a fatty acid Amide ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
본 발명의 화장료 조성물은 여드름 예방 및 치료 효과를 갖는다. 이는 판토텐산의 피지 분비 억제 기능과 녹두 추출물, 자작나무 추출물, 소루쟁이 추출물이 가지는 항염증효과를 활용해 여드름을 개선하는 것이다. 따라서, 본 발명은 피부 노화 방지, 주름 개선, 보습력 개선 및 피부 탄력 개선 용도를 포함하는 것으로 해석된다.The cosmetic composition of the present invention has an acne prevention and treatment effect. This is to improve acne by sebum secretion function of pantothenic acid and the anti-inflammatory effect of mung bean extract, birch extract, Sorugung extract. Accordingly, the present invention is construed to include anti-aging, wrinkle improvement, moisturizing and skin elasticity use.
이하, 본 발명을 실시 예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시 예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로서, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시 예에 제한되지 않는다는 것은 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to the following examples. These examples are only for illustrating the present invention in more detail, and the scope of the present invention is not limited to these embodiments according to the gist of the present invention to those skilled in the art to which the present invention pertains. Will be self explanatory.
(제조예 1) 녹두추출물의 제조Preparation Example 1 Preparation of Mung Bean Extract
녹두 1kg에 70% 에탄올 수용액 10kg을 넣어 상온에서 4일간 정치시켜 추출한 다음, 여과하여 얻은 여액을 감압 농축한 후, 40℃에서 24시간 건조하여 연두색의 분말 22.5g을 얻었다. 이 분말 20g에 정제수:부틸렌글리콜(1:1 중량비 혼합물) 980g을 가한 후 실온에서 교반하여 완전히 용해하여 녹두추출물 1kg을 얻었다.10 kg of 70% ethanol aqueous solution was added to 1 kg of mung beans, and the mixture was left to stand at room temperature for 4 days, followed by extraction. The filtrate was filtered under reduced pressure, and dried at 40 ° C. for 24 hours to obtain 22.5 g of a light green powder. 980 g of purified water: butylene glycol (1: 1 weight ratio mixture) was added to 20 g of this powder, which was then stirred at room temperature to completely dissolve to obtain 1 kg of mung bean extract.
(제조예 2) 자작나무추출물의 제조Preparation Example 2 Preparation of Birch Extract
자작나무의 목피 1kg에 70% 에탄올 수용액 10kg을 넣어 상온에서 4일간 정치시켜 추출한 다음, 여과하여 얻은 여액을 감압 농축한 후, 40℃에서 24시간 건조하여 갈색의 분말 85g을 얻었다. 이 분말 20g에 정제수:부틸렌글리콜(1:1 중량비 혼합물) 980g을 가한 후, 실온에서 교반하여 완전히 용해하여 자작나무추출물 1kg을 얻었다.10 kg of 70% ethanol aqueous solution was added to 1 kg of bark of birch and left to stand at room temperature for 4 days to extract. The filtrate was filtered and concentrated under reduced pressure, and dried at 40 ° C. for 24 hours to obtain 85 g of brown powder. 980 g of purified water: butylene glycol (1: 1 weight ratio mixture) was added to 20 g of this powder, which was then stirred at room temperature to completely dissolve to obtain 1 kg of birch extract.
(제조예 3) 소루쟁이추출물의 제조(Manufacture example 3) Preparation of rust extract
소루쟁이의 뿌리 부분 1kg에 70% 에탄올 수용액 5kg을 넣어 상온에서 4일간 정치시켜 추출한 다음, 여과하여 얻은 여액을 감압 농축한 후, 40℃에서 24시간 건조하여 연두색의 분말 105g을 얻었다. 이 분말 20g에 정제수:부틸렌글리콜(1:1 중량비 혼합물) 980g을 가한 후, 실온에서 교반하여 완전히 용해하여 소루쟁이추출물 1kg을 얻었다.5 kg of 70% ethanol aqueous solution was added to 1 kg of the root of Soru-Jung, and the mixture was left to stand at room temperature for 4 days and extracted. The filtrate was filtered and concentrated under reduced pressure, and dried at 40 ° C. for 24 hours to obtain 105 g of a light green powder. 980 g of purified water: butylene glycol (1: 1 weight ratio mixture) was added to 20 g of this powder, which was then stirred at room temperature to completely dissolve to obtain 1 kg of a sorbite extract.
(실험예 1) 항염증 효과 시험Experimental Example 1 Anti-inflammatory Effect Test
녹두추출물, 자작나무 추출물, 소루쟁이 추출물의 항염증 효과를 측정하기 위해서 평소에 피부병 내지는 피부 알레르기 증상이 없는 사람 20명을 대상으로 항염증 억제 효과를 측정하였다. 실험 대상자의 연령분포는 25 - 35세이고 팔 전박 부위에 항염증 효과를 측정할 5군데의 위치를 표지한 후 크로마미터(chromameter, 미놀타)로 피부의 홍반(a* value)을 측정하였다. 4군데의 측정 위치에 녹두추출물, 자작나무 추출물, 소루쟁이 추출물 5%와 3가지 추출물을 각각 5%씩 섞은 추출 혼합물을 10㎕ 씩 30분 간격으로 4회 적용하고, 나머지 측정 위치에는 비처리하였다. 마지막 적용 30분 후 자극 유발 물질인 메틸 니코티네이트(methyl nicotinate, 0.04%)를 10㎕를 페이퍼 디스크에 흠뻑 적신 후 30초 동안 올려놓았다. 페이퍼 디스크를 제거한 후 흐르는 물에 씻어내었다. 30분 후 도포 부위 4군데와 비처리군 1군데를 크로마미터로 측정하여 실험 전의 홍반과 실험 후의 홍반 정도를 측정하여 항염증 효과를 수학식 1과 같이 계산하였으며, 그 결과(각 군의 평균값)를 표 1에 나타내었다.In order to measure the anti-inflammatory effects of Mung bean extract, birch extract, and Soru-Jung extract, the anti-inflammatory effect was measured in 20 people with no skin disease or skin allergy symptoms. The age distribution of the test subjects was 25-35 years old, and five locations for anti-inflammatory effects were labeled on the forearm of the arm, and then the erythema (a * value) of the skin was measured with a chromatometer (Minolta). An extraction mixture of mung bean extract, birch extract, and 5% of three extracts and 5% of each of the three extracts was applied four times at 30 μl intervals at four measurement positions at 30 μl intervals. . Thirty minutes after the last application, 10 μl of methyl nicotinate (0.04%), a stimulant, was soaked in a paper disk and placed for 30 seconds. The paper disc was removed and rinsed under running water. After 30 minutes, four areas of application and one group of untreated group were measured with a chromameter, and the degree of erythema before the experiment and the erythema after the experiment were measured, and the anti-inflammatory effect was calculated as shown in Equation 1. Is shown in Table 1.
(수학식1)(Equation 1)
항염증 효과 (%) = (처리 전 부위 - 처리 후 부위)/처리 전 부위 * 100Anti-inflammatory effect (%) = (pretreatment-posttreatment) / pretreatment * 100
상기 표 1로부터 알 수 있는 바와 같이, 항염증 효과를 비교 시 각각의 추출물 모두 항염증 효과가 나타났지만, 3개의 추출물 모두가 포함된 복합체에서 가장 우수한 자극 완화 효과를 보여주었다.As can be seen from Table 1, when comparing the anti-inflammatory effect, each extract showed an anti-inflammatory effect, but showed the best stimulating alleviation effect in the complex containing all three extracts.
(제조예 4) 실시예 1 및 비교예 1, 2, 3Production Example 4 Example 1 and Comparative Examples 1, 2, and 3
하기 표 2의 조성비를 가지는 화장료 형태로 판토텐산, 상기 추출물 혼합액이 각각 5중량%가 포함된 실시예 및 비교예의 화장료 조성물을 제조하였다.To the cosmetic composition having a composition ratio of the following Table 2, pantothenic acid, the cosmetic composition of the Examples and Comparative Examples each containing 5% by weight of the extract mixture was prepared.
(실험예 2) 피지 분비 억제 효과 측정(Experimental example 2) sebum secretion inhibitory effect measurement
상기 표 2에 의해 제조된 화장료에 대하여 피지분비 억제 효과를 비교하였다. 피지 분비 억제 효과는 15 ~ 25세의 지성 피부를 가진 여성 40명을 대상으로 각 10명씩 4군으로 나누어서 상기 제조예 4의 실시예 1 및 비교예 1, 2, 3에서 제조된 각 화장료를 아침과 저녁에 하루 2회씩 얼굴에 도포하게 한 후, 3, 6, 9일 후 피부 유분 측정기(Sebum meter SM 815, Courage+Khazaka electronic GmbH, Germany)를 이용해 얼굴의 피지 분비량을 측정하였다. 실험은 25℃ 및 상대 습도 45%의 항온, 항습 조건에서 이루어졌다. 피지분비량을 기본값으로 삼고, 실시예 1 및 비교예 1, 2, 3를 도포한 후, 피지분비량의 변화를 측정하여 피지억제 효과를 평가하고, 초기값 대비 변화한 피지 분비량을 수학식2와 같이 계산하였으며, 그 결과(각 군의 평균값)를 표 3에 나타내었다.The sebum secretion inhibitory effect was compared with respect to the cosmetics prepared by Table 2. Sebum secretion inhibitory effect is divided into four groups of 10 each for 40 women with oily skin of 15 to 25 years old each morning of each cosmetic prepared in Example 1 and Comparative Examples 1, 2, 3 of Preparation Example 4 After application to the face twice a day and in the evening, after 3, 6, 9 days sebum secretion was measured using a skin oil meter (Sebum meter SM 815, Courage + Khazaka electronic GmbH, Germany). The experiment was conducted at constant temperature and humidity conditions of 25 ° C. and 45% relative humidity. Using sebum secretion as the default value, after applying Example 1 and Comparative Examples 1, 2, 3, the sebum secretion effect is measured by measuring the change of sebum secretion amount, and the sebum secretion amount changed from the initial value is expressed as Equation 2 It was calculated and the results (average value of each group) are shown in Table 3.
(수학식2)(Equation 2)
피지분비 억제율 (sebum excretion) = ((St=0 - St=i))/St=0 * 100Sebum excretion = ((S t = 0 -S t = i )) / S t = 0 * 100
St=0 : 도포 전 초기 피지 분비량S t = 0 : Initial sebum secretion before application
St=i : 도포 후 날짜별 피지 분비량S t = i : sebum secretion by date after application
상기 표3의 결과에서 알 수 있듯이 판토텐산을 5중량% 함유하고 있는 실시예 1 및 비교예 1은 판토텐산을 함유하지 않은 비교예 2와 3 보다 피지분비 억제 효과가 우수하였으며, 특히 판토텐산과 추출물 혼합액이 포함된 실시예 1에서 피지 분비억제기능이 가장 우수함을 알 수 있다.As can be seen from the results of Table 3, Example 1 and Comparative Example 1, which contain 5% by weight of pantothenic acid, had better sebum secretion inhibitory effect than Comparative Examples 2 and 3, which do not contain pantothenic acid, and particularly, pantothenic acid and the extract mixture were In Example 1 included it can be seen that the sebum secretion function is the best.
(실험예 3) 실시예 1 및 비교예 1, 2, 3의 항염증 효과 실험Experimental Example 3 Anti-inflammatory Effect Experiments of Example 1 and Comparative Examples 1, 2, and 3
제조예 4에 대한 항염증 효과를 알아보기 위하여 ICR 마우스 5마리씩 총 5군으로 나누어 실험하였다. ICR 마우스의 우측귀를 시험 부위로 하여 시료를 적용하기 전 에탄올로 귀를 깨끗하게 세척하고 시료 20 ㎕를 1일 1회 4일간 지속적으로 도포하고 마지막 도포 1시간 후 우측 귀에 아라키돈산(Arachidonic acid)을 2㎎/ear을 도포하여 1시간 후 귀의 부종(ear edema) 정도를 마이크로미터로 양쪽 귀를 3회씩 반복 측정하였다. 항염 효과는 아라키돈산을 처리군을 기준으로 다음 수학식 3과 같이 부종 억제율을 판정하였으며 그 결과를 다음 표 4에 나타내었다. 그 값은 각 군의 평균값으로 나타내었다.In order to examine the anti-inflammatory effect on Preparation Example 4, five ICR mice were divided into five groups. Using the right ear of the ICR mouse as a test site, clean the ear with ethanol before applying the sample, continuously apply 20 μl of the sample once a day for 4 days, and apply arachidonic acid to the right ear one hour after the last application. After 1 hour of application of 2 mg / ear, the degree of ear edema was repeatedly measured three times on both ears with a micrometer. The anti-inflammatory effect was determined based on the arachidonic acid treated group as shown in Equation 3 below, the edema inhibition rate is shown in Table 4 below. The value is shown by the average value of each group.
(수학식3)(Equation 3)
염증 억제율 (%) = (A-B)/A * 100Inhibition Rate of Inflammation (%) = (A-B) / A * 100
A : 대조군 귀의 변화 (시료처리 후 귀의 두께- 시료처리 전 귀의 두께)A: change of control ear (thickness of the ear after sample treatment-thickness of ear before sample treatment)
B : 시료처리군의 귀의 변화 (시료처리 후 귀의 두께- 시료처리 전 귀의 두께)B: Change of Ear in Sample Treatment Group (Thickness of Ear after Sample Treatment-Ear Thickness before Sample Treatment
상기 표 4의 결과에서 알 수 있듯이 판토텐산 및 혼합 추출액을 함유한 실시예 1이 가장 높은 항염증 효과가 있음을 보여주었다.As can be seen from the results of Table 4, Example 1 containing pantothenic acid and the mixed extract showed the highest anti-inflammatory effect.
(실험예 4) 여드름 환자 대상으로 치료효과의 평가Experimental Example 4 Evaluation of Treatment Effect in Acne Patients
여드름 환자 40명을 대상으로 각 10명씩 4군으로 나누어 상기 제조예 4의 실시예 1 및 비교예 1, 2, 3에서 제조된 각 화장료를 아침과 저녁에 하루 2회씩 세안 후 얼굴에 도포하게 한 후, 한달 뒤 여드름의 개선 정도를 평가하였다. 그 결과를 표 5에 나타내었다.Each of the 40 acne patients were divided into 4 groups of 10 people, each of which was prepared in Example 1 and Comparative Examples 1, 2, and 3 of the Preparation Example 4 to be applied twice a day in the morning and evening after washing the face. After a month, the degree of improvement of acne was evaluated. The results are shown in Table 5.
(제형예 1) 스킨로션Formulation Example 1 Skin Lotion
상기에서 수득한 추출물 혼합액 및 판토텐산을 함유하는 스킨로션을 통상의 방법에 따라 제조하였다.The skin lotion containing the extract mixture obtained above and pantothenic acid was prepared according to a conventional method.
(제형예 2) 로션Formulation Example 2 Lotion
하기의 표 7와 같이 상기에서 수득한 추출 혼합액 및 판토텐산을 함유하는 로션을 통상의 방법에 따라 제조하였다.A lotion containing the extract mixture and pantothenic acid obtained above as described in Table 7 below was prepared according to a conventional method.
(제형예 3) 에센스Formulation Example 3 Essence
하기의 표 8과 같이 상기에서 수득한 추출 혼합액 및 판토텐산을 함유하는 에센스를 통상의 방법에 따라 제조하였다.Essences containing the extract mixture and pantothenic acid obtained as described above in Table 8 were prepared according to a conventional method.
(제형예 4) 팩Formulation Example 4 Pack
하기의 표 9와 같이 상기에서 수득한 추출 혼합액 및 판토텐산을 함유하는 팩을 통상의 방법에 따라 제조하였다.As shown in Table 9 below, a pack containing the extract mixture and pantothenic acid obtained above was prepared according to a conventional method.
(제형예 5) 맛사지크림 Formulation Example 5 Massage Cream
하기의 표 10과 같이 상기에서 수득한 추출 혼합액 및 판토텐산을 함유하는 맛사지크림을 통상의 방법에 따라 제조하였다.Massage creams containing the extract mixture and pantothenic acid obtained as described above in Table 10 were prepared according to a conventional method.
이상에서 상세히 설명한 바와 같이, 본 발명은 판토텐산과 녹두추출물, 자작나무추출물 및 소루쟁이 추출물로 이루어진 군에서 선택된 1종 이상을 함유하는 것으로, 상기 조성물은 피지 분비억제와 항염증 작용에 우수한 상승 작용을 보여 여드름의 예방 및 치료에 탁월한 효과를 보이는 여드름 개선용 화장료 조성물을 제공한다.As described in detail above, the present invention contains at least one selected from the group consisting of pantothenic acid and mung bean extract, birch extract and Soru-lung extract, the composition has excellent synergistic effect on sebum secretion and anti-inflammatory action It provides a cosmetic composition for improving acne showing excellent effect in the prevention and treatment of acne.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060059044A KR100771438B1 (en) | 2006-06-29 | 2006-06-29 | A cosmetic composition for acne improvement having sebum secretion and anti-inflammation effects |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060059044A KR100771438B1 (en) | 2006-06-29 | 2006-06-29 | A cosmetic composition for acne improvement having sebum secretion and anti-inflammation effects |
Publications (1)
Publication Number | Publication Date |
---|---|
KR100771438B1 true KR100771438B1 (en) | 2007-10-30 |
Family
ID=38816297
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060059044A KR100771438B1 (en) | 2006-06-29 | 2006-06-29 | A cosmetic composition for acne improvement having sebum secretion and anti-inflammation effects |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100771438B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101210727B1 (en) | 2010-05-27 | 2012-12-10 | (주)아모레퍼시픽 | Composition for the reduction of skin pores containing glycoproteins extract from plant |
-
2006
- 2006-06-29 KR KR1020060059044A patent/KR100771438B1/en not_active IP Right Cessation
Non-Patent Citations (1)
Title |
---|
미국특허공보 제5612324호 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101210727B1 (en) | 2010-05-27 | 2012-12-10 | (주)아모레퍼시픽 | Composition for the reduction of skin pores containing glycoproteins extract from plant |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100767974B1 (en) | A cosmetic composition for reducing the skin pore containing arctium lappa extracts and cold materials | |
KR101425031B1 (en) | Cosmetic composition for anti-irritation and skin moisturization containing Citrus junos Siebold seed oil and Mangifera Indica seed oil | |
KR101336362B1 (en) | Cosmetic composition | |
KR20180043580A (en) | Composition comprising herbal mixture extracts and hinoki oil for preventing or treating acne and atopic dermatitis | |
KR20090056521A (en) | Cosmetic composition for skin-aging protection and wrinkle improvement comprising the extract of nephelium lappaceum and litchi chinensis sonn as active ingredient | |
KR101100678B1 (en) | Cosmetic Composition comprising plant extracts | |
KR101332215B1 (en) | Cosmetic composition containing fermentated complex of extracts with cryptomeria japonica and nelumbo nucifera for acne improvement and enhancing immune system | |
KR102343166B1 (en) | Cosmetic composition having anti-oxidant, anti-inflammatory, skin soothing, regeneration, elasticity and moisturizing effects which comprise Melaleuca Alternifolia (Tea Tree) Leaf, Artemisia Princeps Leaf, Polygonum Fagopyrum (Buckwheat) Seed and Capryloyl Salicylic Acid | |
KR102327847B1 (en) | Cosmetic composition comprising extracts of lonicera japonica and extracts of aster glehnii for moisturizing the skin | |
CN112402308A (en) | Multi-effect relieving moisturizing lotion and preparation method thereof | |
KR102226179B1 (en) | Cosmetic Compositions for Anti-aging Comprising Extracts of Plants | |
KR20110052095A (en) | Cosmetic composition for moisturizing of skin containing tremella fuciformis extracts | |
JP7338842B2 (en) | wrinkle-improving composition and wrinkle-improving skin cosmetic | |
KR101009763B1 (en) | Natural and oriental herbs complex with anti-hairloss and hair growth stimulating effects | |
KR20210072966A (en) | Nanocapsule composition for skin moisturizing or skin inflammatory improvement comprsing encapsulated centella and calamine | |
KR101034405B1 (en) | Antibiotic composition containing herbal medicine extracts | |
KR101934976B1 (en) | Composition for enhancing skin barrier comprising mixture of Diospyros lotus leaf extract and Curcuma longa extract as effective component | |
KR100771438B1 (en) | A cosmetic composition for acne improvement having sebum secretion and anti-inflammation effects | |
KR20110089793A (en) | A cosmetic composition | |
KR102323174B1 (en) | Cosmetic composition for alleviating skin trouble | |
KR102162377B1 (en) | Extracts derived from natural products and cosmetic composition containing the same, and process for producing the same | |
KR101587446B1 (en) | Cosmetic composition with the IL-S extract by subcritical water extraction with anti-bacterial, moisturizing, itching improvement, increased ceramide, anti-inflammatory effect | |
KR102059620B1 (en) | Cosmetic composition for allevation of acne with the extract of Lycopus lucidus or its fraction | |
KR20180137151A (en) | Cosmetic composition for preventing photo aging comprising Curcuma longa Linne leaf and Hibiscus manihot extracts | |
KR20210143993A (en) | Composition comprising dokdo aster oil |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
G170 | Re-publication after modification of scope of protection [patent] | ||
FPAY | Annual fee payment |
Payment date: 20120920 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20131022 Year of fee payment: 7 |
|
LAPS | Lapse due to unpaid annual fee |